This study has tested the hypothesis that comparison of protein and mRNA expression for ERa and ERb1 by human breast cancers provides novel information relating to the clinical and pathological characteristics of human breast cancers. Expression of ERa and ERb1 was identified in 167 invasive cancers from postmenopausal women treated only with endocrine therapy. The cohort included 143 cases receiving only adjuvant Tamoxifen following surgery. ERa and ERb1 expression was analysed by immunohistochemistry and reverse transcription RT -PCR and compared with clinical progression of individual cancers. ERa protein was closely associated with the corresponding RNA detected by RT -PCR (Chi-square, Po0.001). In contrast, ERb1 protein and mRNA were inconsistent. Although an association was identified between ERa and ERb mRNAs (Chi-square, Po0.001) and between ERa protein and ERb1 mRNA (Chi-square, Po0.027), no association was identified for the ERa and ERb1 proteins detected by immunohistochemistry. ERb1 was not associated with outcome. However, in the absence of ERa, ERb1 protein expression was associated with elevated cell proliferation. There was a trend for the ERb1 protein-positive cases to have a worse outcome, both within the group as a whole as well as within the ERa-positive Tamoxifen-treated cases. This study has confirmed the hypothesis that expression of ERa is an important determinant of breast cancer progression, and has further demonstrated that ERb1 may play a role in the response of breast cancers to endocrine therapy.
Currently, ERa expression is regarded as a reliable prognostic marker with which to predict the response of an individual breast cancer to hormone therapy (Pertschuk and Axiotis, 1999) . However, up to 40% of breast tumours with positive ERa status do not respond to endocrine manipulation (Locker, 1998) . The biological basis of this failure to respond is poorly understood, although modulated expression of ERb has been implicated. Unlike ERa, the antioestrogen -ERb complex inhibits gene transcription when bound to oestrogen response elements (EREs), but acts as an agonist when bound to AP1 elements (Paech et al, 1997) . Therefore, it is possible that antioestrogens may have agonistic effects in ERbpositive breast tumours, resulting in a lack of efficacy of hormonal therapy. This hypothesis is supported by a small number of cases in which overexpression of ERb RNA has been found in Tamoxifenresistant tumours (n ¼ 9) when compared with a Tamoxifensensitive group (n ¼ 8) (Speirs et al, 1999) , but refuted by an immunohistochemical study (Mann et al, 2001) of ERb protein in a larger group (n ¼ 118). Hitherto, only a limited number of studies have used ERb-specific antibodies (Jarvinen et al, 2000; Omoto et al, 2001; Saunders et al, 2002) . These have been based on relatively small numbers of unselected cases and do not all address the relationship of ERb1 expression with patient outcome. Similarly, there are limited studies addressing the specific relationship of ERb with endocrine therapy (Speirs et al, 1999; Mann et al, 2001; Saji et al, 2002) . Hence, the present study has been restricted to an assessment of postmenopausal women receiving endocrine therapy, but no chemotherapy, in order to better address the likely impact of ERb1 expression on response in this common clinical setting.
Recent development of reliable antibodies to ERb, as well as to ERa, has allowed examination of the protein expression of these genes (Taylor and Al-Azzawi, 2000; Choi et al, 2001; Mann et al, 2001; Miyoshi et al, 2001; Omoto et al, 2001; Roger et al, 2001; Skliris et al, 2001 Skliris et al, , 2002 Saji et al, 2002; Saunders et al, 2002) . One previous report suggested a lack of correlation between mRNA and protein for total ERb in 37 out of 61 tumours studied (Shaw et al, 2002) . Consequently, there is a lack of available data on the possible significance of ERb expression in specific treatment cohorts. Furthermore, many previous studies have not adequately defined the precise ERb variants being measured or have used antibodies capable of detecting multiple variants (Skliris et al, 2003) . The relatively high levels of ERb1 protein identified in positive cases may indicate that the PPG5/10 antibody, employed in this study, is among the most sensitive presently available for use in immunohistochemistry with the protocol employed herein (Shaaban et al, 2003a) . Using this antibody, we have already confirmed that the level of ERb1 detected in normal breast epithelium and in premalignant breast lesions is greater than formerly recognised (Shaaban et al, 2003a, b) . Therefore, the purpose of this study was to test the hypothesis that comparison of protein expression levels of ERa and ERb1, together with their respective mRNA levels, in a cohort of postmenopausal primary breast cancer patients treated with surgery and hormonal therapy, would accurately predict the clinical and pathological characteristics of these cancers.
MATERIALS AND METHODS

Patients
Patients undergoing treatment for invasive breast cancer during the period 1993 -1999 were identified within the archival database of the Department of Pathology at the Royal Liverpool University Hospital, and the Cancer Tissue Bank Research Centre (CTBRC) in the same institution. The study population comprised a group of 167 postmenopausal women treated with surgery either with, or without, radiation treatment (Table 1 ). All patients received adjuvant hormone therapy but no chemotherapy. For 143 cases, endocrine therapy consisted of adjuvant Tamoxifen only. Since steroid receptor analysis was not routinely performed until 1996, some cases were subsequently found to be ERa-negative. All cases were subjected to full histopathological review, by three investigators (PAO 0 N, CSF and JPS) according to the UK NHSBSP guidelines (National Coordinating Group for Breast Screening, 1997) . Clinical follow-up data, with informed consent, were recorded by retrospective case-note review. Ethical approval for the study was obtained from all relevant bodies.
Immunohistochemistry
Mouse anti-(human ERb1) monoclonal antibody PPG5/10 was employed to recognise the ERb1 isoform (Serotec Ltd, Kidlington, Oxford, UK). Specificity of the antibody has previously been confirmed by Western blotting in our laboratory (Shaaban et al, 2003b) . For the immunohistochemical detection of ERa, a mouse anti-(human ERa) monoclonal antibody was used (Clone 1D5, Dako Ltd, Ely, Cambridge, UK). Progesterone receptor (PgR) status was measured using a mouse monoclonal anti-PgR antibody (Clone 1A6, Novacastra, Newcastle upon Tyne, UK). Ki67 status was assessed using polyclonal rabbit anti-human Ki67 antibody (Ki67p, Novacastra, Newcastle upon Tyne, UK).
Formalin-fixed and paraffin wax-embedded sections of normal, benign and malignant breast tissues were immunostained for ERa and ERb1. The methods were identical to those previously described (Shaaban et al, 2002) , but with the addition of an overnight incubation at 41C for the ERb1 antibody diluted (1 : 2) in Tris buffer (pH 7.2) containing 1% (w/v) BSA. Immunostaining for ERa was performed by incubating sections with the mouse antiERa monoclonal antibody for 40 min at room temperature. Positive and negative controls were included for each antibody and in each batch of staining.
Analysis was restricted to the epithelial component of all tissues. To maximise consistency of scoring, only nuclei having moderate or strong staining were regarded as positive, irrespective of cytoplasmic staining. The percentage of positively stained epithelial cells was calculated as a proportion of the total number of epithelial cells present. For ERb1, cases were considered as positive only when more than 20% of cells were stained, as previously described (Jarvinen et al, 2000; Miyoshi et al, 2001; Shaaban et al, 2003b) , although other cutoff values were also tested. In contrast with ERa, there has been no agreement on the cutoff value for defining ERb positivity. We chose a cutoff value of 20% as previously described in the studies by Jarvinen et al (2000) and Miyoshi et al (2001) , as well as to be consistent with our previous study (Jarvinen et al, 2000; Miyoshi et al, 2001; Shaaban et al, 2003b) . A 10% cutoff (consistent with that employed in our previous studies) was applied as the conventional criterion to define positive ERa or PgR staining (Sannino and Shousha, 1994) . Ki67 was regarded as elevated if 420% cells were stained, based on the median expression in this cohort of cases.
Reverse transcription (RT) -PCR analysis
Total RNA (5 mg) was provided by the CTBRC. Following DNAaseI digestion (Gibco), RT was performed in duplicate on 0.5 mg of RNA, according to the manufacturers' instructions (Gibco). Reverse transcription reactions incorporated Superscript II Reverse Transcriptase (Gibco), 0.5 mg Oligo (dT) 12À18 and 0.5 ml Prime Recombinant Ribonuclease Inhibitor (Eppendorf). Parallel reactions were performed in which the RT enzyme was omitted and these acted as controls for genomic DNA contamination. Polymerase chain reactions were performed in 20 ml duplicate volumes in 96-well plates, each using 2 ml of a 1/20 dilution of cDNA per reaction (equivalent to cDNA from approximately 2.5 ng of total RNA). All PCR reactions included 0.2 mM dNTPs, 0.5 U of HotstarTaq DNA polymerase (Qiagen) and 1 Â PCR buffer (containing 1.5 mM MgCl 2 , Qiagen). Oligonucleotide primers for RT -PCR and the conditions used are shown in Table 2 and have been previously validated (Moore et al, 1998; Kurebayashi et al, 2000) . Primer concentrations and final MgCl 2 concentrations varied according to Table 2 . The PCR reaction used for ERb is specific for the ERb1 isoform (Moore et al, 1998) . b-Actin and hypoxanthine ribosyltransferase (HPRT) were used as control genes to determine RNA integrity and RT efficiency. Care was taken to ensure that each PCR reaction was limited in cycle number, thus to avoid the plateau phase of the reaction. Oestrogen receptor a RNA was assessed both by ERa PCR and duplex PCR for ERa and actin primers (Kurebayashi et al, 2000) . The data were ERb1 in Tamoxifen-treated breast cancer PA O'Neill et al highly concordant (Chi-square, Po0.001). Polymerase chain reactions for ERb, actin and HPRT were performed individually. Positive controls using MCF-7 cell line cDNA for ERa and testis cDNA for ERb1 were included together with negative controls in each reaction plate. Polymerase chain reaction was performed using Perkin-Elmer 9600 thermal cyclers. All cycling reactions were preceded by a pre-incubation at 941C for 13 min, and were followed within a 3 min final extension at 721C. Cycling conditions for reactions are given in Table 3 .
Polymerase chain reaction products were separated by electrophoresis on gels containing 2.5% Seakem Agarose (Flowgen) and TAE buffer (40 mM Tris acetate, 1 mM EDTA, pH 7.6). Molecular weight markers (PhiX174/HaeIII, Abgene) were included on each gel and DNA was visualised by inclusion of 0.5 mg ml À1 ethidium bromide, scanning with a Molecular Dynamics FluorimagerSI and analysis with ImageQuant version 4.1 software (Molecular Dynamics).
The identity of PCR products was confirmed by direct sequencing using DYEnamic ET Dye Terminator Cycle Sequencing Kit for MegaBACE (Amersham Pharmacia Biotech) and analysed on a MegaBACE 1000 (Molecular Dynamics). Alternatively, PCR products were cloned using TOPO-TA cloning (Invitrogen) prior to sequence analysis.
The presence of a PCR product was assessed independently by two investigators (PAO 0 N and MPAD) and scored as positive where both agreed. Control genes, actin and HPRT were scored as weak or strong positive and individual RT reactions excluded from ER assessment if either gene was negative, or if both were only weak. Cases were considered positive for ERa or ERb if any band was seen regardless of the intensity.
Statistical analysis
All statistical analyses were performed using the SPSS s package (Windows, v.11) . To compare the immunohistochemical percentage values for ERa, PgR, Ki67 or ERb1 in different groups, data were analysed by the nonparametric, two-sided Mann -Whitney test and the two-sided T-test. The nonparametric, two-sided Mann -Whitney test was also used for other ordinal data such as stage and grade. Association between categorical data was assessed by the Chi-squared test and correlations between interval data were tested using Pearson's correlation coefficient. Survival curves were generated using the Kaplan -Meier method for censored data and compared using the log-rank test. Cox's regression models were used for multivariate survival analysis.
RESULTS
RT -PCR
The identities of representative RT -PCR products for each gene were confirmed by sequence analysis. No evidence of artefactual PCR products due to genomic DNA contamination was identified. An example of RT -PCR analysis is shown in Figure 1 . The use of control genes b-actin and HPRT identified 127 cases in which cDNA was considered to be of appropriate quantity and integrity for further analysis. The results of these two control genes were in agreement (Chi-square 27, Po10 À6 ). Reverse transcription -PCR analysis categorised 66% cases as ERa-positive and 68% cases as ERb1-positive (Table 4) . In all, 51% were positive for both ERa and ERb1, 18% negative for both, 17% positive only for ERa and 14% positive only for ERb1. There was some association between RT -PCR results for each ER (Chi-square 12.3, Po0.0005). The distribution of ERb-positive tumours was significantly different between ERa-positive and -negative cases.
Immunohistochemistry
Immunostaining for ERa was performed on 149 cases and was nuclear in all cases regarded as positive. Cytoplasmic-only staining was excluded. Cytoplasmic staining for ERb has been described in several studies and is likely to be genuine and not a staining artefact, although the precise significance of cytoplasmic staining remains unknown. Similar to ERa, cytoplasmic staining without nuclear expression was considered negative, so that only nuclear expression was interpreted as positive to maintain convention and comparability with previously reported studies. Using a cutoff value of 10%, 49 cases (33%) were ERa-negative by immunohistochemistry and the remaining 100 cases (67%) classed as ERapositive. Oestrogen receptor a status was available for a further 11 cases by case-note review (Table 1) . Conventionally, the epithelial component only was scored on assessing ERa and ERb positivity. Oestrogen receptor a was expressed in the epithelial cells, but ERb was also expressed in the stroma.
Immunostaining for ERb1 was performed on 138 cases. Epithelial cells were considered positive if nuclear staining was identified (Figure 2 ). Cytoplasmic staining co-existent with nuclear staining was identified in 64 cases (Figure 2 ). In contrast with ERa, there has been no agreement on the cutoff value for defining ERb positivity. The conventional cutoff value for ERa positivity is 10% (Sannino and Shousha, 1994) . We used a cutoff value of 20% as previously used in the studied by Jarvinen et al (2000) and Miyoshi et al (2001) , as well as to be consistent with our previous study (Shaaban et al, 2003b) . The 20% cutoff (Jarvinen et al, 2000; Miyoshi et al, 2001; Shaaban et al, 2003b) for ERb1 staining resulted in a high proportion of positive cases (85%, 118 cases). The mean percentage of stained cells was 14% for negative cases and 69% for positive cases (T-test, Po0.0005). The proportion of immunostained cancer cells was considerably more variable for ERb1 than for ERa (Figure 3 ). Immunohistochemical data for both ERa and ERb1 were available for 137 cases. In all, 56% of all cases were positive for both ERs (Table 4 ) and only 3% were negative for both ERa and ERb1. However, a significant proportion (29%) was negative for ERa but expressed ERb1, compared to a smaller number of cases expressing ERa alone (12%). There was no significant association between ERa and ERb1 status (Chi-square 1.6, P ¼ 0.21). No correlation between the proportion of immunopositive cells was identified (Pearson's R ¼ À0.007, P ¼ 0.94).
Relationship between ER RT -PCR and immunohistochemistry
Reverse transcription -PCR for ERa was performed on 121 cases with known ERa immunohistochemistry status. There was a significant association between the two techniques (Chi-square 47, Po0.0005). For ERa RT -PCR-negative cases, the median expression of ERa by immunohistochemistry was zero. For ERa RT -PCR-positive cases, median expression of ERa by immunohistochemistry was 90% (Figure 3) . The proportion of immunostained cells was significantly higher in cases positive for ERa by RT -PCR (both T-test and Mann -Whitney Po0.0005).
Both RT -PCR and immunohistochemistry were assessed for ERb1 in 101 cases (Table 4 ). No significant relationship was identified between RT -PCR and immunohistochemistry (Chi-square 0.8, P ¼ 0.78). This was true for all ERb1 immunohistochemical cutoffs tested. There was no significant association between ERa RT -PCR and ERb1 immunohistochemistry 
Relationship between ER immunohistochemistry and other parameters
Oestrogen receptor a expression, determined by immunohistochemistry, was associated with PgR status and Ki67 status ( No significant association was detected between ERb1 immunohistochemical expression and grade of tumour, axillary nodal status, ERa status or PgR status. There was an association with greater proliferation, measured by Ki67 staining. The mean % Ki67-positive cells was greater (T-test P ¼ 0.043) in the ERb1-positive cases (28%) than in the ERb1-negative cases (18%). This was true even when considering ERa-negative cases, but not ERapositive cases; Ki67 is greater (T-test P ¼ 0.022, Mann -Whitney P ¼ 0.028) in ERb1-positive/ERa-negative cases (mean 51%) than in ERb1-negative/ERa-negative cases (mean 18%). Using a median cutoff of 60% (but not a cutoff at 20%), there was a trend for the presence of lymphovascular invasion and larger tumours in ERb1-positive cases, as seen for RT -PCR.
Relationship between ER RT -PCR and other parameters
While there was no relationship between ERb1 RT -PCR status and Ki67 staining and only a trend for an association with PgR, there was an association (Figure 4 , Table 5 ) between these parameters and ERa RT -PCR status. Oestrogen receptor a RT -PCR-positive Table 5 ).
Cases that were ERb1-positive/ERa-negative by RT -PCR had larger tumours (mean 4.1 cm) than those that were ERb1-positive/ ERa-positive (2.7 cm, T-test Po0.0005), ERb1-negative/ERa-negative (2.2 cm, T-test P ¼ 0.001) or ERb1-negative/ERa-positive (3.1 cm, Mann -Whitney P ¼ 0.012). These ERb1-positive/ERanegative tumours were also of higher stage than the other three subgroups defined by RT -PCR .
Relationship between ER and disease outcome
In order to examine the possible effect of ERb1 status in a cohort of patients receiving the same endocrine treatment, outcome data have been restricted to those 143 women receiving adjuvant Tamoxifen, but without primary endocrine treatment and no primary or adjuvant chemotherapy. In this cohort, ERa expression determined by immunohistochemistry (Figure 4) , stage, grade, size, nodal status, Ki67 staining and PgR were all associated with the expected manner that measures of breast cancer relapse-free survival (RFS) and demonstrated significant differences in breast cancer-associated survival (BCS) and overall survival (OS). All these markers had significant log-rank scores for RFS, BCS and OS (all log-rank Po0.021). Lymphovascular invasion only exhibited a 
Statistical test used was chi-square (CS), Mann-Whitney (MW); n.s. ¼ not significant. *using a cut-off of 60% positive cells for ERb1. trend for poorer outcome (P ¼ 0.08 for RFS, P ¼ 0.09 for BCS). In multivariate analysis, ERa immunohistochemistry status was independently significant for RFS in the presence of each other parameter apart from grade and Ki67 status. Considering multiple parameters, the strongest significance was attached to nodal status, followed by grade. Positive ERa immunohistochemical scores were associated with better RFS using all cutoff points from the standard 10 -90% positive cells (Po0.001). Positive ERa RT -PCR status was associated with a better outcome, as measured by RFS (Figure 4) , but not BCS (P ¼ 0.055) or OS (P ¼ 0.21). No significant association with outcome was seen for ERb1 RT -PCR (Figure 4 ; P ¼ 0.65 RFS, P ¼ 0.27 BCS, P ¼ 0.87 OS). There was a trend for better survival in cases immunohistochemically negative for ERb1 ( Figure 4C ). Only four of the 17 (24%) ERb1-negative cases relapsed, when compared to 51 of 103 (50%) ERb1-positive cases (Fisher's exact test, P ¼ 0.029). This was not true for any other cutoff tested.
Within the adjuvant Tamoxifen cohort, 91 cases were ERapositive by immunohistochemistry and therefore typical of those women who are likely to receive adjuvant endocrine treatment today. Within this subgroup grade, nodal status and Ki67 were all significant markers of outcome (RFS, BCS and OS all log-rank Po0.01), as were stage (RFS log-rank Po0.01, BCS P ¼ 0.03), PgR (BCS, RFS and OS all log-rank Po0.05) and size (OS log-rank P ¼ 0.015). ERb1 RT -PCR showed no association with any measure of outcome, but as before a trend for a worse outcome in ERb1 immunohistochemically positive cases was seen (RFS, logrank P ¼ 0.11; Fisher's exact test, P ¼ 0.061).
DISCUSSION
This study has confirmed the initial hypothesis that comparison of protein expression levels for ERa and ERb1, together with their respective mRNA levels, are indicators of the clinical and pathological characteristics of a cohort of postmenopausal primary breast cancer patients treated only surgically and thereafter with Tamoxifen therapy. The findings confirm the differential expression of these two oestrogen receptors by human breast carcinomas, with a high degree of correlation between the immunohistochemical and RT -PCR data for ERa being identified.
Unlike the findings for ERa, this study did not reveal a strong correlation between ERb RT -PCR and the corresponding immunohistochemistry. Identification of the technical and biological reasons for this apparent discrepancy is of fundamental importance to understanding the role of ERb in human breast cancer. Recently, Omoto et al (2002) reported that protein and RNA levels are often not in agreement, but did not provide any cogent explanation for this discrepancy. Three potentially important factors require consideration: First, this apparent discrepancy might be explained by relative lack of sensitivity of RT -PCR when compared to the 20% immunohistochemical cutoff (where 29% of cases were RT -PCR negative and immunohistochemically positive). Previously, it has been reported that mRNA levels for ERb are lower and more diverse than those for ERa (Iwao et al, 2000) and that levels of ERb1 are lower than for other ERb variants (Leygue et al, 1999; Iwao et al, 2000) . Either of these phenomena would contribute to a lower sensitivity for detection of ERb1 by RT -PCR. When testing for a possible correlation between ERb1 identified by RT -PCR and by immunohistochemistry, various cutoff levels were assessed. However, there was no value that gave a statistically significant association with the RT -PCR data. In contrast, correlations occurred between ERb1 RT -PCR and with both ERa immunohistochemistry and RT -PCR, which were not recapitulated at the protein level and which would account for other reports of relationships between the two ERs. Second, while immunohistochemistry is an in situ technique in which data are obtained subjectively, RT -PCR is performed on disaggregated tissue preparations in a quantitative manner. Hence, expression of ERb1 mRNA from other cell types might account for the seven cases that were RT -PCR positive and immunohistochemically negative, but not the 29 RT -PCR-negative but immunohistochemically positive cases. While a theoretical possibility, this explanation is interesting since nonepithelial stromal cells of normal breast tissues have been found to be weakly ERbpositive while stromal cells of the unusual phylloides tumours were found to strongly express ERb (Shaaban et al, 2003b) .
Translational or post-translational control mechanisms are likely to play a significant role in ERb expression in some cases of breast cancer. We have already shown that modulation of ERs is both complex and indirect, the latter mechanisms including altered expression of homeostatic protein hsp-27 (O'Neill et al, 2003) . It is now recognised that the precise structure of many proteins expressed by individual genes varies with the phenotypic status of an individual cell. These 'splice variants', while encoded within the normal genome, become expressed according to the overall status of the tissue in which they originate (e.g. embryonic, adultproliferative or malignant). Such differences are already recognised to be important, with respect to splice variants of some proteins (e.g. voltage-gated ion channels), but are yet to be proven for others (e.g. ERs), although there is substantial circumstantial evidence for this selection. If splice variation is an important factor in the expression of ERb, then use of monoclonal antibodies directed to epitopes in the wild type that become spliced out and hence nonexpressed in the cancers provide erroneous information. Recognition of this caveat is important for accurate interpretation of such data. Multiple forms of ERb splice variants occur in normal breast tissue and breast malignancies (Leygue et al, 1999; Omoto et al, 2002) . Unfortunately, most previous RT -PCR analysis studies have used primers unsuitable for distinguishing individual isoforms. Recent production of antibodies suitable for detection of individual ERb isoforms (Saunders et al, 2002; Skliris et al, 2002) should allow a better understanding of the complex factors regulating hormone responsiveness of human breast carcinomas to emerge (O'Neill et al, 2003; Shaaban et al, 2003b ).
In the current series, and in accordance with previous immunohistochemical reports (Enmark et al, 1997) , ERb1 was predominantly localised to the nuclei of epithelial cells and of myoepithelial cells, as well as stromal cells (Taylor and Al-Azzawi, 2000; Speirs et al, 2002) . Oestrogen receptor b1 expression was identified in 85% of invasive cancers using a 20% immunohistochemical cutoff and the median expression was 60%. The reported proportion of ERb1-positive invasive carcinomas varies appreciably among previous studies and might be explained by differences in the specificity of the antibodies, methods of antigen retrieval and different thresholds used to define positive staining Shaaban et al, 2003a ). In the current cohort, 56% of cancers were positive for both ERa and ERb1 by immunohistochemistry, while 29% of cancers were ERa-negative and ERb1-positive. Given the potential discrepancies due to antibody usage and staining technique, together with the robust levels of ERb1 staining, these numbers are in agreement with those reported in other immunohistochemical studies of ERb1 (Jarvinen et al, 2000; Omoto et al, 2002; Saunders et al, 2002) , which describe 48 -74% of cases as ERb1-positive/ERa-positive and 8 -20% as ERb1-positive/ERa-negative. Unlike ERa, which is usually expressed in only a minority of cells in normal epithelium and aberrantly expressed at high levels in the majority of cells in many breast cancers, ERb1 is apparently expressed in the majority of cells in normal breast and this expression is maintained in most breast cancers at a variety of levels. Persisting but varied expression of ERb1 in the presence or absence of greater amounts of ERa indicates that the role played by the interaction between ERa and ERb1 during mammary carcinogenesis and in subsequent cancers is likely to be complex. Thus, this study has pinpointed a cellular ERb1 in Tamoxifen-treated breast cancercontrol mechanism that, in human breast cancer, requires specific and detailed analysis.
Only one previous study has reported ERb immunohistochemistry in adjuvant Tamoxifen-treated patients (Mann et al, 2001) . In contrast to our present findings, the previous adjuvant study suggested ERb-positive patients to have a better survival when compared with ERb-negative patients. Overall, the immunostaining reported in the previous study appeared weaker than observed here, with only 66% of 118 cases being ERb-positive at a 10% cutoff, when compared to 85% positive for ERb1 at a 20% cutoff. Since that study utilised an antibody with broad specificity, possible contribution of other ERb variants is unclear. It is possible that the findings of that study are due to expression of variants ERb2 and ERb5 since, at the RNA level, these have been shown to be greater than ERb1 in breast cancers (Leygue et al, 1999; Omoto et al, 2002) . The isoform of ERb to have the greatest effect on outcome for breast cancer patients is yet to be confirmed. Although only seen here for RT -PCR, others have reported some association between ERa and ERb staining (Jarvinen et al, 2000; Omoto et al, 2001) and it is possible that the unreported ERa status of the cases previously reported has some influence on the data (Mann et al, 2001) . In this study, no association was found between ERb and grade of tumour, progesterone receptor, or nodal status, thus broadly in agreement with other studies. However, in this cohort of post-menopausal women treated with Tamoxifen therapy, ERb-positive cancers tended to have poorer RFS than ERb-negative cancers. This finding was not entirely due to the presence of ERb in some ERa-negative cases, since a trend was still present in the ERa-positive subgroup.
This study lends some support to the original hypothesis that expression of wild-type ERa influences the effectiveness of antioestrogen therapy. Furthermore, antioestrogens (e.g. Tamoxifen) of particular affinity for the specific splice variant of oestrogen receptor expressed by each individual breast carcinoma may have agonistic effects in ERb-positive tumours, hence resulting in a lack of efficacy of hormonal therapy (Speirs et al, 1999) . There is evidence that this might also be true for ERb2, since this protein was associated with poor response to Tamoxifen in a neoadjuvant setting (Saji et al, 2002) . However, our data contradict less critical reports that are imprecise with respect to patient groups examined and ERb variants detected. Further studies are now being performed to clarify the roles of different ERb splice variants in breast cancers treated by hormonal manipulation. These will include cohorts of patients selected according to clinical and treatment criteria in order to determine the importance of ERb in breast cancer management and outcome.
